Ara 290 (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 84 | Sarcoidosis | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02039687 (ClinicalTrials.gov) | January 2014 | 16/1/2014 | Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis | A Double Blind, Placebo Controlled Phase 2 Dose Ranging Study of the Effects of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis | Neuropathy of Sarcoidosis | Drug: ARA 290;Other: Placebo | Araim Pharmaceuticals, Inc. | NULL | Completed | 18 Years | 70 Years | All | 64 | Phase 2 | United States;Netherlands |
| 2 | EUCTR2013-003016-45-NL (EUCTR) | 11/09/2013 | 15/08/2013 | study the safety and effects of different doses of ARA 290 administered subcutaneously on the corneal nerve fiber density and symptoms of neuropathic pain in sarcoidosis patients. | A double blind, placebo controlled Phase 2 dose ranging study of the effects of ARA 290 on corneal nerve fiber density and neuropathic symptoms of patients with sarcoidosis - DOSARA | small fiber neuropathy;Therapeutic area: Body processes [G] - Biological Phenomena [G16] | Product Name: ARA 290 Product Code: ARA 290 INN or Proposed INN: ARA 290 | Araim Pharmaceuticals | NULL | Not Recruiting | Female: yes Male: yes | 64 | Phase 2 | United States;Netherlands |